The aminothiol WR1065 exerts selective cytoprotective effects in normal cells compared to cancer cells and has clinical applications for the protection of normal cells in cancer patients undergoing radio-or chemotherapy. There is evidence that p53 is activated in response to WR1065. To examine the effects of WR1065 on the signalling pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in the presence or absence of wild-type p53 were used. Treatment with WR1065 resulted in G1 cell cycle arrest in the p53-positive cell line but not in the p53-negative cell line. Long-term exposure resulted in minimal apoptosis of either cell line. Changes in gene expression in p53-positive or -negative cells treated with WR1065 were examined using commercial human stress and cancer gene arrays (Clontech Atlas arrays). Genes found to be specifically upregulated in a p53-dependent manner included coproporphyrinogen oxidase, ICErel-II cysteine protease, macrophage inhibitory cytokine-1 (also known as placental transforming growth factor beta), S100A4, and Waf1/ p21. However, most proapoptotic genes typically upregulated by p53 in response to DNA damage were not activated. These studies show that WR1065 specifically modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observation that this agent elicits essentially p53-dependent, cell cycle arrest responses.
Introduction
The tumor suppressor protein p53 is stabilized and functionally activated in response to a variety of cellular stress signals, including both genotoxic and nongenotoxic signals (reviewed in Pluquet and Hainaut, 2001) . Stabilization of p53 is accompanied by an increase in functional activity of the protein, as evidenced by an increase in transport of p53 from the cytoplasm into the nucleus and a subsequent increase in DNA binding and transcriptional regulation of specific target genes by p53. The sets of target genes activated or repressed by p53 in response to a specific stress signal depend on various factors such as the nature and intensity of the stress, ensuing modifications of the p53 protein, interactions of p53 with other cellular proteins, and the genetic makeup of the cells expressing p53 (Hainaut and Mann, 2001; Vousden, 2002; Vousden and Lu, 2002) .
Most DNA-damaging signals activate p53 through a complex signalling cascade involving kinases that phosphorylate p53 on a series of residues located in the N-terminus, as well as histone acetylases targeting specific lysines in the C-terminus of the protein. Non-DNA-damaging signals (such as signals generated by unprogrammed or excessive cell proliferation) induce p53 by activating the p14arf protein that binds to and sequesters Mdm2, thus allowing p53 to escape degradation and undergo activating post-translational modifications. Several other stress pathways converge on p53. The c-Jun-N-terminal kinase (Jnk) when inactive binds to p53 and facilitates its degradation. However, upon activation in response to many forms of chemical or biological stress, Jnk phosphorylates p53 at Thr81, dissociates from p53, and participates in both p53 stabilization and activation (Fuchs et al., 1998) . Thus, the p53 protein lies at the receiving end of several crossinteracting stress signalling pathways, explaining its extreme sensitivity to multiple forms of physical, chemical, and biological stresses (Pluquet and Hainaut, 2001) .
Mounting evidence suggests that the ability of p53 to bind to target DNA and to regulate the expression of an associated gene is largely influenced by its redox state (Hainaut and Milner, 1993; Rainwater et al., 1995; Parks et al., 1997; Meplan et al., 2000; Merwin et al., 2002) . The p53 protein contains a structural 'redox sensor' in the form of several critical cysteine residues located in the DNA-binding surface of the protein, three of which are involved in the coordination of a zinc atom (Cho et al, 1994; Rainwater et al., 1995) . In fact, p53 lies at the center of a network of redox interactions that may fine-tune its activation in response to various stimuli and thus determine the subsequent fate of a cell in response to genotoxic and nongenotoxic insults (Hainaut and Mann, 2001) . Since modulation of the redox state is a mechanism by which the function of wild-type p53 and possibly mutant p53 can be manipulated, we were particularly interested in studying the effect of WR1065 on p53 function, both because of the potential ability of this aminothiol to modulate the redox state of p53 and because of its use as a cytoprotector of normal cells in cancer treatment protocols.
WR1065 is the active form of the pro-drug amifostine (WR2721), a cytoprotective agent used clinically to protect normal cells from the effects of radio-and chemotherapeutic treatments of cancerous tissue (Poplin et al., 1994; Capizzi, 1996; Kemp et al., 1996) . Phosphorylated WR2721 is converted by alkaline phosphatase to the active aminothiol WR1065 (Calabro-Jones et al., 1985) upon crossing plasma membranes. Overall, WR1065 has been shown to protect cells from oxidative injury (Polla et al., 1990) , likely due to its ability to scavenge highly reactive OH À radicals (Marzatico et al., 2000) . The protective effect of WR1065 may also be due in part to its ability to prevent the rise in intracellular Ca 2 þ , which occurs in response to oxidative injury (Polla et al., 1990) . In agreement with this antioxidant effect, we have found no evidence of oxidative stress induced in MCF7 cells treated with WR1065, and in fact have shown protection by WR1065 against oxidative stress induced by hydrogen peroxide (H 2 O 2 ) treatment (North et al., 2000; Pluquet et al., 2003b) .
Several other possible modes of action of WR1065 may play a role in its ability to protect normal cells against the cytotoxic and genotoxic effects of radio-and chemotherapy. WR1065 binds to transcription factors NF-kB and AP-1, as well as to p53, and enhances their binding to and transactivation of specific target DNAs (Shen et al., 2001) . It stabilizes and activates wild-type p53 in treated cells (North et al., 2000) and, in its presence, p53 upregulates expression of p21/Waf1 and downregulates progression of cells through the cell cycle. The mechanism for this long-lasting activation of p53 is not the result of activation of a DNA damage pathway (Pluquet et al., 2003b) , but rather appears to involve phosphorylation of Jnk and its dissociation from p53, such that p53 is no longer targeted for breakdown (Pluquet et al., 2003a) . Interestingly, WR1065 activates the binding of purified wild-type p53 to its cognate DNA target in a redox-dependent manner (Pluquet et al., 2003b) .
Understanding the effects of WR1065 on p53 may help in understanding the mechanisms by which WR1065 exerts its protective effects on cells exposed to radiation and chemotherapeutic agents. In this study, we have investigated the effects of WR1065 on the transcriptional regulatory activity of p53, particularly in view of its ability to act as a reducing agent. In order to characterize specific target genes regulated by wild-type p53 in response to treatment with WR1065, we have analysed the hybridization of cDNAs from isogeneic cell lines, differing only in p53 status, to both human stress and cancer gene arrays and have identified a subset of genes specifically modulated by p53 in response to WR1065.
Results

Treatment with WR1065 results in p53-dependent cell cycle arrest in HCT116 cells
For this study, we used the colon carcinoma cell lines HCT116 (expressing wild-type p53) and its derivative HCT116À/À (p53-negative), in which the TP53 gene locus is interrupted by the introduction of a DNA cassette that effectively blocks the production of a fulllength p53 transcript (Bunz et al, 1998) . Subconfluent cells were exposed to WR1065 in medium supplemented with 4 mM aminoguanidine (AG), to prevent the degradation of WR1065 into cytotoxic metabolites by intracellular Cu-dependent amine oxidases (Meier and Issels, 1995) . Tests were undertaken to determine at what dosage WR1065 plus AG has a cytotoxic effect on the cell lines. Concentrations of WR1065 ranging from 0.5 to 1.0 mM were without effect, while a concentration of 1.5 mM WR1065 resulted in a slight increase in cytotoxicity (data not shown). We chose, therefore, to use a concentration of 1.0 mM WR1065 in the ensuing experiments.
As expected from previous results obtained with WR1065 treatment of other cell lines (North et al., 2000 (North et al., , 2002 , there was an increase in the level of p53 protein in HCT116 cells in response to WR1065 treatment ( Figure 1 ). This increase was seen in both cytoplasmic and nuclear fractions, but was particularly noticeable in the nuclear fraction. The increase in p53 protein was accompanied by an increase in the consensus DNA-binding activity of p53 (Figure 1) , and by an increase in p21, the product of the p53 target gene Waf1 (Figure 1 ). Concomitantly, HCT116 cells responded to treatment with a more marked G1 cell cycle arrest than HCT116À/À cells (Figure 2 ), suggesting that the increase in p21 was responsible, given the known inhibition of cdk2 by p21 (Harper et al., 1993) . In fact, this p53-dependent G1 arrest was still present after 120 h of treatment with WR1065 (data not shown). The weak p21 band present in the Western blot of the HCT116À/À cells (Figure 1 ) was consistent with the weak G1 arrest response seen in these cells in response to WR1065 (Figure 2 ), but in this case, the mechanism for p21 expression is clearly not p53-related.
The role of p21 in cell cycle arrest of HCT116 cells was confirmed by cell cycle analysis of WR1065-treated HCT116 cells deficient for p21 (p21À/À cells) (Waldman et al., 1995) , in which there was no evidence of G1 arrest after 24 h of treatment (Figure 2 ). Interestingly, there was also no evidence of G2 arrest after WR1065 treatment of p21À/À cells, in contrast to the G2 arrest seen when these cells were treated with chemotherapeutic DNA-damaging agents (Waldman et al., 1996) .
Long-term exposure to WR1065 has a minimal effect on apoptosis of p53-competent, p53-null, or p21-null cells, whereas etoposide triggers apoptosis of p53-null and p21-null cells but not p53-competent cells Since amifostine is used to protect normal cells over the course of treatment of tumor cells with radio-or chemotherapy, we were interested in determining what long-term effects its metabolite WR1065 might have on the viability of HCT116 and HCT116À/À cells, differing only in the status of p53. To determine if apoptosis had been triggered in either of the cell lines treated with WR1065, extracted proteins were electrophoresed, blotted, and immunodetected with antibody to poly (ADP)ribose polymerase (PARP). An early response of cells to apoptotic signals is cleavage of 113 kDa PARP to 89 and 24 kDa fragments by proteases from the ICE family (Kaufmann et al., 1993; Lazebnik et al., 1994) . However, anti-PARP detected only higher molecular weight PARP and no smaller cleavage products after treatment of either cell line with WR1065 ( Figure 3) . The results argue against a significant induction of apoptosis in response to WR1065 in either p53-positive or -negative HCT116 cells.
In the course of these experiments, it was noted that the molecular weight as well as the amount of PARP increased at 48 and 72 h after treatment with WR1065 in the p53-competent HCT116 cells compared to the p53-null HCT116À/À cells (Figure 3 ). Since PARP is known Figure 1 Treatment with aminothiol WR1065 leads to an increase in p53 protein, p21 protein, and specific DNA-binding activity of p53. Subconfluent HCT116 and HCT116À/À cells were treated with WR (1 mM WR1065 þ 4 mM AG), AG (4 mM AG alone), or CN (1 Â PBS) for 16 h at 371C. After 16 h treatment, cytoplasmic and nuclear extracts were prepared and analysed on Western blots for expression of p53 (top panel, nuclear extracts) and p21 (middle panel, cyotplasmic extracts). Nuclear extracts were analysed by EMSA for the ability to retard radiolabelled target DNA (bottom panel) Figure 2 WR1065 treatment causes G1 arrest of HCT116 cells (upper panel, left-hand bar graphs), with much less effect on HCT116À/À cells (upper panel, right-hand bar graphs) and no effect on the cell cycle distribution of HCT116 p21À/À cells (lower panel). Colon carcinoma cells, differing only in the presence or absence of p53 or p21, were treated as in Figure 1 , but for 24 h at 371C. Cells were processed with TEST-PLUS DNA-staining kit, and DNA content was measured by FACSCalibur flow cytometry. Results were analysed using CellQuest and ModFit LT2.0 software Figure 3 Levels of PARP, poly(ADP)ribosylation of PARP, and p53 increase in p53-positive cells relative to p53-negative cells in response to WR1065. Nuclear proteins from HCT116 or HCT116À/À cells at 24, 48, or 72 h after treatment with WR1065 were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE), and Western blots were probed with antibody to PARP, poly(ADP)ribose, or p53. Blots were incubated with 21 antibody coupled to horseradish peroxidase (HRP) and reacted with ECL to undergo self-ADP-ribosylation (Kawaichi et al., 1981) , we probed the Western blots with antibody to poly(ADP)ribose. The results indicated that the increase in molecular weight of PARP was indeed due to ADPribosylation of the protein (Figure 3 ). PARP and p53 are known to interact physically (Malanga et al., 1998 ), but it is not known why ADP-ribosylation of PARP is dependent on the presence of p53. As expected, the level of p53 protein is elevated in WR1065-treated HCT116 cells compared to the level in HCT116 cells treated with AG alone (Figure 3 ), but is somewhat less at 48 and 72 h than at 24 h.
As a positive control for apoptosis, we examined the percentage subdiploid cells resulting from WR1065 treatment of the three isogeneic HCT116 cell lines (p53-competent, p53-null, and p21-null) for a total of 24, 72, and 120 h, and compared this with the percentage subdiploid cells resulting from etoposide treatment of the cell lines over the same period of time. It is known that the DNA-damaging agents adriamycin and etoposide induce apoptosis in HCT116p53À/À cells and HCT116p21À/À cells, while HCT116p53 þ / þ cells do not undergo apoptosis (Waldman et al., 1996; Bunz et al., 1999) . Interestingly, after 72 h of etoposide treatment, 33% of the p53-null cells and 39% of the p21-null cells were apoptotic, whereas only 4% of the p53-competent cells were apoptotic ( Figure 4 ). In contrast, the response of the three cell lines to 72 h of treatment with WR1065 was markedly different, with the percentage subdiploid cells ranging from 2 to 6% in cell cycle analysis of the three isogeneic cell lines ( Figure 4 ). Analysis of DNA ladder formation confirmed that the high percentages of subdiploid p53-null and p21-null cells resulting from etoposide treatment were indeed due to apoptosis (data not shown). Both the results from cell cycle analysis and those from analysis of PARP suggest that apoptosis is not induced by WR1065 treatment of HCT116 cells, whether p53-positive or -negative.
Gene array analysis of untreated HCT116 and HCT116À/À cells shows similar expression profiles, with the exception of S100A4 expression in p53-competent cells HCT116 cells have often been used for gene inactivation in vitro since they contain a mutation in the hMLH1 gene that makes them permissive to homologous recombination. Although HCT116 (p53-competent) and HCT116À/À (p53-null) cell lines both derive from the same parental cells, the disabling of p53 in the HCT116À/À cells, combined with mutation of the hMLH1 gene (Miyafuji et al., 2001) , might have led to significant divergence between the two cell lines. It was important, therefore, to compare the expression profiles of the cell lines in the absence of any treatment before testing the effect of WR1065 on gene expression in the presence versus absence of p53. Hybridization of cDNA probes from untreated HCT116 and HCT116À/À cells to human cancer 1.2 expression arrays (Clontech) showed that there was no significant divergence in gene expression between the two cell lines (data not shown), with the exception of calvasculin/S100A4 expression in p53-competent cells but not in p53-null cells. Changes in expression of this gene in response to WR1065 are described later. Having established the overall similarity in the basal level of gene expression in HCT116 and HCT116À/À cells in the absence of any treatment, we Many stress-response genes are upregulated by WR1065 in p53-competent cells compared to p53-null cells.
Since WR1065 has the potential to protect cells against stress, in particular through its thiol-dependent reducing activity, we used a commercial array with 234 genes involved in the response of cells to physical and chemical stress (Clontech human stress array). Radiolabelled cDNAs were synthesized from poly-A þ RNA and hybridized to the expression arrays. Table 1 shows stress-related genes up-or downregulated twofold or more by treatment of p53-positive cells relative to p53-negative cells with WR1065 for 16 h. The greatest differential increase in expression in p53-competent cells occurred for Waf1 (eightfold), consistent with the increase in p21 protein level and G1 cell cycle arrest shown in Figures 1 and 2 , respectively. The gene that showed the second largest change in expression (3.4-fold) encodes coproporphyrinogen oxidase, a mitochondrial enzyme that catalyses a rate-limiting step in the pathway of heme biosynthesis. This enzyme may contribute to the maintenance of the mitochondrial redox balance in response to stress. However, its regulation by p53 has never been reported. The other stress array genes upregulated twofold or more belong to families of genes involved in redox control, DNA repair, and protein breakdown (Table 1 ). The only one of these upregulated genes, other than p21, known to be directly transactivated by p53 is mdm2 (Barak et al., 1993) . The other upregulated genes are most likely indirectly affected by the stabilization of p53 in response to WR1065 treatment, although the possibility remains that some may be target genes directly regulated by p53. Interestingly, there are a greater number of stress genes upregulated than downregulated by WR1065 in the presence of p53, suggesting that p53 is responsible for eliciting an overall stress response in treated cells.
Cancer arrays show up-or downregulation of the expression of specific genes in p53-competent versus p53-null cells
To extend our analysis of the expression of genes altered in response to WR1065, we hybridized cDNAs from HCT116 versus HCT116À/À cells treated with AG alone or AG þ WR1065 to human cancer 1.2 expression arrays, containing 1176 genes known to be altered in human cancers. An approximately equal number of genes on these arrays were significantly up-or downregulated twofold or more in response to WR1065 treatment of the HCT116 cell lines (Table 2) . Treatment resulted in overexpression of four genes by greater than threefold in p53-positive cells compared to their expression in p53-negative cells: S100A4, ICErel-II (caspase-4), Waf1/p21, and macrophage inhibitory cytokine (MIC-1), also known as placental transforming growth factor b (PTGFb) ( Table 2) . None of several p53-regulated proapoptotic genes present on the array were affected at the selected cutoff (twofold change in expression) for inclusion in Table 2 . The only apoptosis-related gene significantly upregulated in this experiment was cysteine protease ICErel-II. Its increased expression is puzzling in view of the fact that the p53-competent cells are not undergoing apoptosis, at least not during 120 h of WR1065 treatment (Figure 4 ). In the context of the present study, however, we did not investigate this gene further. S100A4 RNA and protein are upregulated in response to WR1065 S100A4, a calcium-binding protein implicated in tumor progression and metastasis , binds to p53 and interferes with the transactivation of target genes by p53 . When WR1065-treated HCT116 cells were compared with treated HCT116À/À cells, a marked difference (20-fold greater) in expression of S100A4 RNA was noted (Table 2) . However, as discussed earlier, this difference in expression was in large part due to expression of S100A4 in untreated HCT116 cells, but not in the Western blot analysis of the S100A4 protein in cytoplasmic extracts showed that S100A4 protein increased approximately twofold in HCT116 cells treated with WR1065 for 24 h, whereas absolutely no S100A4 protein was detectable in treated HCT116À/À cells ( Figure 5 ). The marked difference in the basal expression level of S100A4 is curious in view of the fact that these two cell lines are isogeneic except for the presence or absence of p53. Our results strongly support the hypothesis that S100A4 expression is p53-dependent, either through direct transcriptional control by p53 or through indirect mechanisms involving the interaction of p53 with other transcription factors. The p53-dependent expression of S100A4 in our cell system agrees with the results of Daoud et al. (2003) , and suggests that the S100A4 promoter may contain a p53 consensus DNA-binding site, as found in the S100A2 promoter (Tan et al., 1999) .
PTGFb mRNA and protein are expressed in response to WR1065 in p53-competent cells PTGFb has been shown to be transactivated by p53 (Tan et al., 2000; Baek et al., 2002) and has been implicated in the growth arrest and apoptotic functions of p53 (Tan et al., 2000; Baek et al., 2001; Liu et al., 2003) . Northern blot analysis confirmed a significant increase in PTGFb RNA in p53-competent HCT116 cells after 12 h of treatment with WR1065, with very little change in p53-null HCT116À/À cells treated in a similar fashion (Figure 6a ). Radioactively labelled RNA probes confirmed that this mRNA indeed corresponded to sense rather than antisense PTGFb RNA (data not shown). Northern analysis of RNA harvested at shorter time points of treatment (2, 4, and 6 h) indicated that the increase in expression occurred sometime between 6 and 12 h of WR1065 treatment (data not shown). The level of PTGFb RNA in the p53-competent cells increased up to 24 h of treatment with WR1065, at which time its expression was 25-fold greater than that in p53-null cells (Figure 6a ), suggesting that p53 plays a significant role in regulating the transcription of PTGFb. However, the Figure 5 Expression of S100A4 protein increases in HCT116 cells, but not in HCT116 À/À cells, treated with WR1065. Cytoplasmic extracts from HCT116 and HCT116À/À cells treated with WR1065 were subjected to SDS-PAGE, blotted, and probed for S100A4, followed by 21 antibody coupled to HRP and ECL. Independent detection of jnk1/jnk2 shows no change and serves as a control for protein loading Aminothiol WR1065 alters transcriptional regulation by p53 K Mann and P Hainaut slight increase noted in expression of PTGFb RNA in HCT116À/À cells by 24 h of WR1065 treatment (Figure 6a ) suggests that there are other regulatory factors in the cell capable of transactivating this gene that are not dependent on p53.
To determine if the increased expression of PTGFb RNA in response to WR1065 translated into an increase in PTGFb protein, we developed an immunopurified antibody against a 17-peptide sequence designed from the unique C-terminus region of PTGFb (Bootcov et al., 1997; Paralkar et al., 1998) . This antibody was used to detect the levels of protein expressed after 48 h of treatment of HCT116 and HCT116À/À cells with WR1065. Since PTGFb is a secreted protein (Paralkar et al., 1998; Tan et al., 2000) , we looked at the amount of extracellular PTGFb protein as well as the level of intracellular protein. Western blots demonstrated approximately twofold more PTGFb in the cytoplasm and 1.5-fold more PTGFb in TCA precipitates of conditioned medium from p53-competent cells compared to p53-null cells after 48 h of WR1065 treatment (Figure 6b) . Secreted PTGFb has a molecular weight of 12 kDa, while cytoplasmic PTGFb is 19 kDa in size, compatible with the notion that the secreted protein is processed from a higher molecular weight intracellular form. Significantly, we also detected a 38 kDa PTGFb form in conditioned medium from WR1065-treated HCT116 cells, which was not present in medium from treated HCT116À/À cells (Figure 6b ). This protein is presumably the same as the unprocessed pro-PTGFb precursor (40 kDa) detected by Bauskin et al. (2000) under reducing conditions and accounts for an even greater difference in PTGFb protein between the two cell lines in response to WR1065.
PTGFb RNA is also upregulated in a p53-dependent manner in response to treatment of cells with hydrogen peroxide
There is little published evidence for PTGFb being involved in the DNA damage response elicited by p53 activation in response to DNA-damaging agents. To determine if the increased expression of PTGFb mRNA was a p53-specific response to a reducing agent, such as WR1065, or whether it might also be observed in response to other p53-inducing agents, we analysed the effect of H 2 O 2 on its expression. H 2 O 2 is a welldocumented inducer of DNA strand breaks and an activator of p53, and its oxidizing properties are opposite to the reducing properties attributed to WR1065. HCT116 cells and HCT116À/À cells were exposed to 200 mM H 2 O 2 for varying periods of time before extraction of RNA. Northern blots showed a marked increase in expression of PTGFb mRNA in p53-positive HCT116 cells, which was already present at 5 h after treatment with H 2 O 2 (Figure 7 ). This response was dependent on the presence of p53 and did not occur in the HCT116À/À cells. The overall trend of expression of PTGFb in H 2 O 2 -treated HCT116 cells differed from that in WR1065-treated HCT116 cells, with the level of PTGFb mRNA decreasing by 17 h of treatment with H 2 O 2 (Figure 7 ) but still increasing after 24 h of treatment with WR1065 (Figure 6a ). Most importantly, p53-dependent upregulation of PTGFb mRNA occurs in response to treatment of cells with both oxidizing and reducing agents. (1 mM) for 48 h. CM was collected from treated cells, and proteins in 7 ml of medium were precipitated with 10% TCA and washed with 95% ethanol. The pellets were resuspended in 1 Â PBS, and the equivalent of 1/20 Â volume of each TCA precipitate was loaded onto 10% Tricine gels, along with cytoplasmic extracts (10 mg). The gel was blotted onto Millipore PVDF-P SQ (0.2 mm pore size) membrane in the presence of 35% methanol, and detected with antibody to PTGFb, followed by 21 antibody coupled to HRP and ECL 
Transfection of H358 cells with PTGFb does not affect cell viability and does not protect cells from cell death induced by wild-type p53 transfection
PTGFb overexpression results in a reduction in cancer cell growth and viability, presumably through induction of G1 cell cycle arrest and an effect on apoptosis (Li et al., 2000; Baek et al., 2001) . In contrast, the increased expression of PTGFb in our WR1065-treated HCT116 cells did not result in a significant increase in apoptosis in the time frame that we studied (Figure 4 ). To test whether the apoptotic effect of PTGFb noted by others might be cell type specific, we transfected p53-null human non-small cell lung carcinoma H358 cells with vector DNA alone or with PTGFb DNA, and selected cells containing the transfected DNA by inclusion of G418 in the medium. We found no noticeable difference in the number of G418-resistant cells remaining attached to the plate 9 days after transfection ( Figure 8 ). In addition, cotransfection of H358 cells with wild-type p53 DNA in combination with either vector DNA alone or PTGFb DNA showed that cell death induced by wildtype p53 was not prevented by coexpression of PTGFb. These data were quantified by optical density measurements of scanned images of the transfected plates, using Scion Image software. Plates transfected with vector alone or with vector þ PTGFb had a mean optical density more than fivefold greater than plates transfected with vector þ wild-type p53 or vector þ wild-type p53 þ PTGFb (Figure 8 legend) .
Discussion
The use of genetically matched cell lines, differing only in the status of p53 or the status of p21, has enabled us to understand more fully the mechanism by which WR1065 cytoprotects p53-competent cells. The pattern of response observed in HCT116 cells suggests that WR1065 successfully sets into motion a sequence of events in which p53-competent cells are arrested in the G1 phase of the cell cycle and not one in which apoptosis is triggered by p53. The primary effector of this cell cycle arrest is p21/WAF1, as shown by the lack of G1 arrest in WR1065-treated isogeneic p21-deficient HCT116p21À/À cells (Figure 2 ). The effect of WR1065 on apoptosis is minimal, as demonstrated by the absence of any significant subdiploid population of cells (Figure 4 ), the absence of morphologically detectable cell death, and the lack of caspase-mediated PARP degradation (Figure 3) . Our results contrast with the results of Lee EJ et al. (2003) in which amifostine increases apoptosis in p53-negative HCT116 cells, whereas the presence of p53 protein actually confers resistance to this amifostine-induced apoptosis. However, the high concentration (3.8 mM) of amifostine used in the study of Lee et al. could, on conversion of the prodrug to the aminothiol, result in a concentration of WR1065 greater than the 1.5 mM dosage, which we have shown to be cytotoxic. In a number of experimental systems, WR1065 exerts antimutagenic and cytoprotective effects at concentrations ranging between 100 mM and 1 mM and can even induce p53 accumulation at concentrations as low as 50 mM (North et al., 2000) . Also, the absence of AG in the culture medium in the experiments by Lee EJ et al. (2003) may result in the generation of toxic products from amifostine breakdown. Previously, transcription of several genes has been reported to be altered by treatment with WR1065: p21 is upregulated by treatment of cells containing wild-type p53 (North et al., 2000) , as are fas, gadd45, and mdm2 (Shen et al., 2001) , whereas MnSOD is upregulated in response to WR1065 activation of NF-kB (Kataoka et al., 2002) . In our experiments, two of the genes upregulated on the human stress and cancer gene arrays by more than threefold in response to exposure of p53-competent cells to WR1065 are controlled by p53: Waf1/p21 and PTGFb. The upregulation of these genes in response to the aminothiol is dependent on the presence of wild-type p53 in the HCT116 carcinoma cells, but would presumably also occur in nonmalignant cells expressing wild-type p53. Although our data show an upregulation of S100A4 in response to WR1065, the high basal level of expression of S100A4 in HCT116 cells argues against a major role for the upregulation of The promoter of Waf1 contains a well-characterized p53-binding site (El-Deiry et al., 1993) , and increased transcription of p21 in HCT116 cells (Figure 1 ) in response to WR1065 is in keeping with the preferential arrest of p53-competent cells in the G1 phase of the cell cycle (Figure 2 ). An increase in binding of p53 protein to consensus target DNA sequences (Figure 1) is required for increased transactivation of specific target genes and could be due to one of several possible mechanisms: an increase in the level of p53 elicited by WR1065 (North et al, 2000; Pluquet et al., 2003a) , a WR1065-driven alteration in the redox state of p53 toward reduction, or a combination of both. Direct interaction of WR1065 with p53 (Shen et al., 2001 ) allows for the modification of cysteine residues in p53 by the free sulfhydryl group of WR1065. WR1065 was in fact found to be more effective than DTT in activating recombinant p53 binding to consensus target DNAs (Pluquet et al., 2003b) , suggesting that the aminothiol can act as a reducing agent in vitro. Clearly, there is also an increase in the level of p53 protein in response to treatment with WR1065 (Figure 1 ), so it is likely that both of the postulated mechanisms are at work and are responsible for the increased p53 binding to target DNA sequences.
Transcriptional upregulation of PTGFb also occurs in response to treatment of p53-competent HCT116 cells, but not p53-null HCT116À/À cells, with WR1065 ( Figure 6 ). This differential expression is in keeping with the fact that PTGFb is known to be a p53 target gene, with a promoter that contains two binding sites essential for p53-mediated induction of PTGFb (Li et al., 2000; Tan et al., 2000; Baek et al., 2002) . Independent discovery of this gene has resulted in a number of different names for PTGFb, including MIC-1 (Bootcov et al., 1997) and nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1; Baek et al., 2001) , along with different postulated functions for the protein.
Our study is the first to demonstrate an increase in expression of PTGFb in response to WR1065 treatment of p53-competent cells, but PTGFb is also upregulated in response to resveratrol (Baek et al., 2002) and by treatment of p53-competent cells with topotecan and etoposide/doxorubicin, inhibitors of topoisomerase I and topoisomerase II, respectively (Baek et al., 2002; Daoud et al., 2003; Yang et al., 2003) . Importantly, the increased expression of PTGFb in HCT116 cells treated with H 2 O 2 (Figure 7 ) as well as with WR1065 ( Figure 6 ) suggests that p53-dependent upregulation of PTGFb in response to both oxidizing and reducing agents may be an attempt by p53 to protect cells from redox perturbations.
Although it is generally agreed that PTGFb is a p53-regulated gene, there are conflicting views as to its function in cells exhibiting an upregulation. Overexpression of PTGFb from a recombinant adenoviral vector in p53-positive MCF-7 cells results in increased expression of p21 followed by G1 cell cycle arrest (Li et al., 2000) , providing an alternative mechanism for the WR1065-elicited cell cycle arrest we observe in our p53-competent cells (Figure 2 ). PTGFb protein is also involved in invasiveness of cancer cells (Lee DH et al., 2003) , senescence of p53-positive tumor cells treated with doxorubicin (Chang et al., 2002) , and induction of apoptosis (Li et al., 2000; Tan et al., 2000; Baek et al., 2001; Liu et al., 2003) . However, since our WR1065-treated HCT116 cells do not undergo apoptosis in response to increased expression of PTGFb, it is difficult to reconcile our data with the findings of Baek et al. (2001) in which NAG-1-transfected HCT116 cells exhibit increased basal apoptosis and reduced soft agar cloning efficiency. The induction of apoptosis in the HCT116p53À/À and HCT116p21À/À cells by etoposide (Figure 4) clearly indicates that the HCT116 cells are capable of responding to adverse conditions by undergoing apoptosis, but do not do so when treated with WR1065 for 120 h.
In summary, the response of p53 to the presence of WR1065 appears to be a selective one in which genes involved in G1 cell cycle arrest and in stress response are upregulated. It is well known that wild-type p53 can selectively trigger either cell cycle arrest or apoptosis in response to genotoxic or nongenotoxic insults to the cell. Upregulation of p53 levels by WR1065 and the subsequent induction of G1 arrest would serve to protect nonmalignant cells containing wild-type p53 from the radio-or chemotherapeutic treatment of neighboring malignant tumor cells. Preferential arrest of nonmalignant cells in G1 would allow repair of damaged DNA before DNA replication occurs and would prevent the detrimental incorporation of mutations into the genomes of these cells. In contrast, malignant cells containing nonfunctional mutant p53, or no p53, would not undergo G1 arrest when treated with WR1065, and therefore the effectiveness of the radio-or chemotherapy would not be altered by inclusion of this drug in the treatment regime.
Materials and methods
Cell lines and treatments
Colon carcinoma cell lines HCT116 expressing wild-type p53, isogeneic HCT116À/À with a homozygous knockout of p53 (Bunz et al., 1998) , and isogeneic HCT116p21À/À with a homozygous knockout of p21 (Waldman et al., 1995) were kindly provided by Dr Burt Vogelstein. Cells were grown in McCoy's medium with 10% fetal bovine serum (PAA, Linz, Austria), 2 mM glutamine, and penicillin/streptomycin. Cells were treated with either phosphate-buffered saline (PBS), AG dissolved in complete medium, or aminothiol WR1065 (provided by USB) dissolved in PBS and flushed with argon to prevent oxidation. Cells were pretreated with AG at a final concentration of 4 mM for 10 min prior to the addition of WR1065 at a final concentration of 1 mM.
Cell cycle analysis
Cells were harvested by trypsinization, washed with PBS, resuspended in citrate/sucrose/DMSO solution provided in the TEST-PLUS DNA-staining kit (Becton Dickinson), and stored at -801C until analysed. Cells were then processed, and nuclei stained with propidium iodide. DNA content was measured on a FACSCalibur flow cytometer, and results analysed using CellQuest and ModFit LT2.0 software (Becton Dickinson).
Protein extraction and Western blots
Cells were harvested by trypsinization, washed with PBS, and lysed in EMSA buffer-A (20 mM HEPES at pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, and 0.1% NP-40) containing protease inhibitors (0.5 mM PMSF, 0.5 mg/ml leupeptin, 2 mg/ml aprotinin, and 0.7 mg/ml pepstatin A) for 10 min at 41C. Lysates were centrifuged at 300 g for 4 min at 41C, and supernatant saved as the cytoplasmic fraction. Nuclear pellets were then extracted for 30 min at 41C in EMSA buffer-B (same as EMSA buffer-A, but with 500 mM NaCl) with protease inhibitors, centrifuged at 15 000 g for 15 min at 41C, and supernatant saved as the nuclear fraction. The extracts were stored at À801C until further use.
Protein concentrations were determined by Bradford assay (Bio-Rad). Equal amounts of protein were mixed with Laemmli sample buffer, resolved on 10% or 12.5% SDSpolyacrylamide gels, and electroblotted onto PVDF membranes (Roche). Primary antibodies used were as follows: rabbit anti-human MIC-1 at a 1 : 750 dilution (CovalAb, Oullins Cedex, France); DO-7 (murine a-human p53) at a 1 : 1000 dilution (Dako); murine a-WAF1/p21 at a 1 : 200 dilution (Oncogene); rabbit a-PARP at a 1 : 2000 dilution (Boehringer Mannheim); rabbit a-poly(ADP)ribose at a 1 : 2500 dilution (Alexis, San Diego, CA, USA; kindly provided by Dr Zhao-Qi Wang); rabbit anti-human S100A4 at a 1 : 1000 dilution (Dako); and murine anti-human jnk1/ jnk2 at a 1 : 1000 dilution (PharMingen). After incubation with HRP-coupled goat a-mouse IgG or goat a-rabbit IgG at a 1 : 3000 dilution (Dako), proteins or specific modifications were revealed using ECL enhanced chemiluminescence detection as specified by the manufacturer (Amersham).
Electrophoretic mobility gel-shift assay
Preparation of nuclear extracts for analysis by electrophoretic mobility gel-shift assay (EMSA) has been described above. The double-stranded p53 consensus binding sequence p53con (5 0 -GGACATGCCCGGGCATGTCC-3 0 ) was end-labelled with [g-32 P]ATP (B3000 Ci/mmol, Amersham) as described previously (Verhaegh et al., 1997) . Similar amounts of nuclear protein extract were added to the binding reaction, containing 0.5 ng of 32 P-labelled double-stranded oligonucleotide, 2 mg sonicated herring sperm DNA (Promega), 5 mg bovine serum albumin (BSA), and 4 mM DTT, in a total volume of 30 ml. Monoclonal antibody PAb421 (100 ng/reaction, Oncogene) was added to stabilize the p53-DNA complexes. After incubation for 30 min at room temperature, 17 ml aliquots were loaded onto a 4% low ionic strength gel and protein-DNA complexes separated in 1/3 Â TBE buffer containing 0.1% Triton X-100 at 200 V for 1 h (Parks et al., 1997) . Gels were fixed, dried, and exposed to X-ray film (Eastman-Kodak) overnight at À801C.
Total RNA extraction and Northern blot analysis
Control and treated cells were washed with cold PBS, and total RNA extracted with Trizol reagent (Gibco-BRL) according to the specifications of the manufacturer. RNA precipitates were washed with 75% ethanol, dried, resuspended in RNase-free water, and incubated at 601C for resuspension. RNAs were quantitated using Yo-Pro-1-iodide (Molecular Probes), using an RNA ladder as the standard. Fluorescence was measured in 96-well plates (Falcon) with the Fluoroskan Ascent FL fluorimeter (Labsystems) at excitation 485/emission 538, and analysed with Fluoroskan Ascent FL 2.2 software.
RNA samples (10 mg each of total RNA), along with an RNA ladder with a range of 0.24-9.5 kb in size (Gibco/BRL), were prepared in formaldehyde-formamide-MOPS, heatdenatured, mixed with loading buffer plus ethidium bromide, and loaded onto an agarose-formaldehyde-MOPS gel and run at 20 V overnight in MOPS buffer. RNA was transferred from the gel onto Hybond-N nylon membrane (Amersham) by upward capillary transfer in 20 Â SSC buffer overnight. After transfer, the membrane was washed in 2 Â SSC, dried at room temperature for 15 min, and then baked in an 801C oven for 1-2 h.
Radioactive DNA probe was prepared by random nonamer priming of a purified EcoRI-restricted PTGFb DNA fragment (pcDNA3-PTGFb, kindly provided by Y Sun), using the Megaprime kit and [a-32 P]dCTP (3000 Ci/mmol) according to the recommendations of the supplier (Amersham). Labelled DNA probe was separated from unincorporated radionucleotide using a Chroma Spin-200 DEPC-H 2 O column (Clontech) and then heat-denatured. During probe preparation, the Northern blot was prehybridized in Church solution (0.5 M NaP buffer, pH 7.2, 7% SDS, and 1% BSA) at 651C for a minimum of 4 h. DNA probe was mixed with fresh Church solution and hybridized to the membrane in a hybridization roller incubator at 651C overnight. The blot was then washed with 2 Â SSC, 0.1% SDS solution at 651C, followed by 0.2 Â SSC, 0.1% SDS at 651C and exposure to Kodak BioMax MR film overnight at À801C. mRNA isolation, cDNA synthesis, and gene array analysis Cells were harvested after treatment with AG and/or WR1065, and poly-A þ RNA was isolated using an mRNA kit (Boehringer Mannheim) and magnetic particle separators, as specified by the supplier. After precipitation and quantification of RNA with Yo-Pro, 2 mg of each poly-A þ RNA was treated with DNase I, requantitated, and 1 mg of each used to synthesize a cDNA probe in the presence of [a-32 P]dATP (3000 Ci/mmol) and primer mix provided in either the Atlas human stress or human cancer 1.2 cDNA expression array kit (Clontech). Labelled cDNA probe was purified on Chroma Spin-200 DEPC-H 2 O columns, and equal Cerenkov counts were used for side-by-side hybridizations to array membranes. Prehybridization and hybridization were carried out according to the specifications of Clontech using ExpressHyb solution and heat-denatured sheared salmon testes DNA. After hybridization overnight at 681C in a hybridization roller incubator, membranes were washed in 2 Â SSC, 1% SDS, followed by 0.1 Â SSC, 0.5% SDS at 681C. The membranes were exposed to Kodak BioMax MR film at À801C. Quantification of labelled cDNAs hybridized to the arrays was performed with AtlasImage 1.5 software (Clontech), using a scanned image of the autoradiogram.
Transfection
On reaching approximately 30-40% confluency, H358 cells on 5 cm plates were transfected with 2 mg DNA/plate in the presence of FuGene (Roche), as specified by the supplier. Plates were transfected with 0.25 mg of vector DNA (pcDNA3) alone, 0.25 mg pcDNA3-PTGFb alone, 0.25 mg pCMVp53wt (murine p53, kindly provided by P Tegtmeyer) plus 0.25 mg pcDNA3, or 0.25 mg pCMVp53wt plus 0.25 mg pcDNA3-PTGFb. pBSK (Stratagene) DNA was used to increase total DNA to 2 mg/plate. Fresh RPMI medium þ 10% fetal bovine serum þ G418 (final concentration of 750 mg/ml) was added to the cells the following day and every 2-3 days thereafter. At 9 days after transfection, the plates were fixed with 200-proof ethanol, stained with Giemsa, and scanned images were quantitated with Scion Image software.
